You Treat Your Patients as Individuals. So Do We.

MPS2 delivers the accuracy needed to provide the best care for all your patients.

>75%

Most men with an elevated PSA will have a prostate biopsy negative for clinically significant cancer.

The Challenge

You regularly grapple with whether to proceed with biopsies in men with an elevated PSA. You know most of these men do not have clinically significant prostate cancer, but incomplete information keeps you from knowing who is truly at risk. And, under the traditional “biopsy all” approach, 75% of prostate biopsies are negative for clinically significant cancer. With stakes so high, you need the insights provided by the next generation of biomarker testing.

99%

92-99% NPV, depending on clinical context

The Solution

MyProstateScore 2.0 (MPS2) is the most comprehensive and flexible prostate cancer risk assessment tool, optimized for unrivaled accuracy for both previous negative biopsy and biopsy naïve patients, providing unparalleled insights to guide clinical decisions.

Next-Generation Urine Biomarker Testing

Unrivaled Accuracy

MPS2 sets a new standard by identifying up to half of men who are likely to have a negative result for clinically significant prostate cancer on biopsy. MPS2 delivers unparalleled confidence in deciding to defer biopsy with an industry-leading negative predictive value (NPV) of up to 99%.

Tailored to Each Patient

Tailor MPS2 to meet the specific needs of each patient by ordering it either as a biomarker-only test or by including clinical risk factors. The test can also be performed with or without a digital rectal exam (DRE) before urine collection, based on patient preference or clinical considerations.

Convenient Collection Options

MPS2 offers flexible sample collection, either in-office or at home, with or without a digital rectal exam (DRE), offering accessible testing experiences while maintaining high accuracy.

No Special Shipping Requirements

Unlike other tests that may degrade with fluctuating temperature, MPS2 samples do not need to be refrigerated or shipped on ice, reducing the risk of compromised samples. Samples can be collected and shipped any day of the week, eliminating shipping hassles for both providers and patients.

18 Unique Gene Transcripts

MPS2 analyzes 18 unique gene transcripts within models shown to predict clinically significant cancer across a variety of patient cohorts.

T2:ERG
SCHLAP1
OR51E2
APOC1
PCAT14
CAMKK2
PCA3
NKAIN1
B3GNT6

TFF3
SPON2
PCGEM1
TRGV9
TMSB15A
ERG
KLK3
KLK4
HOXC6

T2:ERG
SCHLAP1
OR51E2
APOC1
PCAT14
CAMKK2
PCA3
NKAIN1
B3GNT6

TFF3
SPON2
PCGEM1
TRGV9
TMSB15A
ERG
KLK3
KLK4
HOXC6

Research and Publications

Lynx Dx and its research partners at the University of Michigan are dedicated to the highest quality of research excellence, including the breakthrough discovery of the novel T2:ERG gene fusion for which Dr. Arul Chinnaiyan was awarded the 2022 Sjoberg Prize.

See Publications